Charles Birbara

Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore.